卡度尼利单抗联合贝伐珠单抗和化疗治疗持续性、复发性或转移性宫颈癌的成本效益分析表1

数据集获取（Figshare）

• 源站标题：Table 1_Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer.doc
• DOI：10.3389/fimmu.2025.1594786.s001
• 发布日期：2025-06-25
• 文件数：1 个
• 文件总体积：557.57 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table_1_Cost-effectiveness_analysis_of_cadonilimab_plus_bevacizumab_and_chemotherapy_for_persistent_recurrent_or_metastatic_cervical_cancer_doc/29397227

命令行下载

curl -L -o "Table 1_Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer.doc" "https://ndownloader.figshare.com/files/55626740"

文件清单

• Table 1_Cost-effectiveness analysis of cadonilimab plus bevacizumab and chemotherapy for persistent, recurrent, or metastatic cervical cancer.doc（557.57 KB）

文件总体积 557.57 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

ObjectiveThe aim of this study is to investigate the cost-effectiveness of cadonilimab plus bevacizumab and chemotherapy in the first-line treatment for patients with persistent, recurrent, or metastatic cervical cancer from a healthcare system perspective in China.
MethodsA partitioned survival model was established to estimate the total costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) over a 10-year time horizon. Clinical data was sourced from the COMPASSION-16 trial; direct medical costs and utilities were obtained from a public drug bidding database and published literature. The robustness of the model was assessed via scenario, one-way and probabilistic sensitivity analyses.
ResultsCadonilimab plus bevacizumab and chemotherapy yielded an additional cost of $31,654.02, with an additional QALY of 0.36, resulted in an ICER of $88,533.51/QALY compared with bevacizumab and chemotherapy. Utility values of progression-free survival (PFS), patient weight and price of cadonilimab were the most influential parameter on ICER. The probability of cadonilimab plus bevacizumab and chemotherapy being cost-effective was 0% at the WTP threshold of $38,042.49 per QALY. When the price of cadonilimab reduced by 72%, cadonilimab plus bevacizumab and chemotherapy would represent an economically viable treatment regime.
ConclusionCadonilimab plus bevacizumab and chemotherapy may not be a cost-effective option as the first-line treatment in persistent, recurrent, or metastatic cervical cancer.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fimmu.2025.1594786.s001（source: https://frontiersin.figshare.com/articles/dataset/Table_1_Cost-effectiveness_analysis_of_cadonilimab_plus_bevacizumab_and_chemotherapy_for_persistent_recurrent_or_metastatic_cervical_cancer_doc/29397227）。